Please use this identifier to cite or link to this item:
|dc.title||Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: Clinical and therapeutic implications|
|dc.identifier.citation||Ong, K.W., Teo, M., Lee, V., Ong, D., Lee, A., Chieh, S.T., Vathsala, A., Toh, H.C. (2009-09-01). Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: Clinical and therapeutic implications. Clinical Cancer Research 15 (17) : 5350-5358. ScholarBank@NUS Repository. https://doi.org/10.1158/1078-0432.CCR-08-2979|
|dc.description.abstract||Purpose: EBV-positive smooth muscle tumor (EBV+SMT) is a rare disease with no established therapy. We describe the largest single institution analysis in renal transplant recipients. It aims to define its clinical features and determine the expression of EBV latent genes as well as key molecular pathways. Experimental Design: Patients with EBV+SMT were identified from the Singapore General Hospital Renal Transplant Registry database. These tumors were investigated for expression of EBV latent genes with Southern blots, EBV latent antigens, mammalian target of rapamycin (mTOR), Akt, p70 S6 kinase, and vascular endothelial growth factor using immunohistochemistry, as well as methylation status of cancer-related genes using methylation-specific PCR. Results: Eight were found to be EBV+SMT in 1,123 transplant patients. All displayed indolent clinical courses and were unresponsive to immunosuppression reduction. Complete tumor regression was seen in one patient following administration of sirolimus. These tumors display the full range of known EBV latent genes. Immunohistochemistry with total and phosphorylated mTOR and Akt were positive for all patients, and vascular endothelial growth factor was positive in 25% of patients, suggesting activation of the mTOR/Akt pathway. Methylation of RASSF1A was found in all tissue samples, whereas promoter hypermethylation of RARβ, GSTP1, DAPK, and p14 was observed in some samples. Conclusions: Our results suggest that these tumors display a EBV type III latency pattern. The mTOR pathway is also activated. EBV may play a role in silencing RASSF1A. EBV-specific immunotherapy, mTOR inhibitors, and demethylating agents are possible therapeutic options in this disease. © 2009 American Association for Cancer Research.|
|dc.contributor.department||DUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE|
|dc.description.sourcetitle||Clinical Cancer Research|
|Appears in Collections:||Staff Publications|
Show simple item record
Files in This Item:
There are no files associated with this item.
checked on Jul 13, 2020
WEB OF SCIENCETM
checked on Jul 13, 2020
checked on Jul 11, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.